EUVIMEDOpdag EUVIMED
Crossref

Targeted Therapy in Pediatric Langerhans Cell Histiocytosis: Describing a Novel Strategy to Minimize Long‐Term Exposure While Maintaining Efficacy

Natalia Wojciechowska iD, Alexandra E Richards iD, Aly Anthony, Maranda Diaz, Kelly Vallance iD, Chelsee Greer, Anish Ray iD

Pediatric Blood & Cancer · 2025

DOI: 10.1002/pbc.32016 ↗

At a glance

Journal article in Pediatric Blood & Cancer, 2025. Written by Natalia Wojciechowska and 6 co-authors. Institution: Cook Children's Medical Center, Fort Worth, Texas, USA. Major MEDLINE topics: Histiocytosis, Langerhans-Cell, Pyridones, Pyrimidinones, Molecular Targeted Therapy. Cited 6 times so far (Crossref); 38 references.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Background

Langerhans cell histiocytosis (LCH) is a rare malignancy driven by MAPK pathway activation and often involves BRAF V600E mutations. Targeted therapy with trametinib, a MEK inhibitor, is a promising alternative to conventional chemotherapy. Procedure We retrospectively analyzed the records of patients treated with trametinib either at relapse or as front‐line therapy between 2020 and 2024.

Results

Fifteen pediatric patients received trametinib either at diagnosis ( n = 6), relapse ( n = 7), or due to chemotherapy intolerance ( n = 2). Molecular testing identified MAPK pathway mutations in 11 patients. The median age at treatment initiation was 5 years (range: 0.1–16.5). Notably, five of these patients started trametinib before the age of 1. The median treatment duration was 2.2 years (range: 0.1–4.7 years). All 15 patients achieved favorable responses without concerns regarding growth and development. The adverse effects included rash (40%) and diarrhea (13%), which were all mild and were managed with temporary dose adjustments. A self‐weaning dosing strategy minimized long‐term exposure while maintaining disease control.

Conclusion

Our data suggest that trametinib is a safe and effective therapy for pediatric LCH with broad efficacy and tolerability. However, prospective studies are needed to confirm these findings and refine targeted treatment protocols.

Subjects

MeSH terms (MEDLINE)

Histiocytosis, Langerhans-CellPyridonesPyrimidinonesMolecular Targeted TherapyProtein Kinase InhibitorsHumansMaleFemaleChildAdolescentChild, PreschoolRetrospective StudiesInfantFollow-Up StudiesPrognosisMutation

Author keywords

langerhan's cell histiocytosismolecular geneticspediatric oncology

Substances

trametinibPyridonesPyrimidinonesProtein Kinase Inhibitors

Authors and institutions

  • Cook Children's Medical Center, Fort Worth, Texas, USA.
  • Anne Burnett Marion School of Medicine at TCU, Fort Worth, Texas, USA.

ORCID profiles: Natalia Wojciechowska, Alexandra E Richards, Kelly Vallance, Anish Ray

Cite

APA

Wojciechowska, N., Richards, A. E., Anthony, A., Diaz, M., Vallance, K., Greer, C., & Ray, A. (2025). Targeted Therapy in Pediatric Langerhans Cell Histiocytosis: Describing a Novel Strategy to Minimize Long‐Term Exposure While Maintaining Efficacy. Pediatric Blood & Cancer. https://doi.org/10.1002/pbc.32016

Vancouver

Wojciechowska N, Richards AE, Anthony A, Diaz M, Vallance K, Greer C, et al. Targeted Therapy in Pediatric Langerhans Cell Histiocytosis: Describing a Novel Strategy to Minimize Long‐Term Exposure While Maintaining Efficacy. Pediatric Blood & Cancer. 2025. doi:10.1002/pbc.32016

BibTeX
@article{Wojciechowska2025,
  author = {Wojciechowska, Natalia and Richards, Alexandra E and Anthony, Aly and Diaz, Maranda and Vallance, Kelly and Greer, Chelsee and Ray, Anish},
  title = {Targeted Therapy in Pediatric Langerhans Cell Histiocytosis: Describing a Novel Strategy to Minimize Long‐Term Exposure While Maintaining Efficacy},
  journal = {Pediatric Blood & Cancer},
  year = {2025},
  doi = {10.1002/pbc.32016}
}
Start for free →